FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3146788730> ?p ?o ?g. }

• W3146788730 endingPage "791" @default.
• W3146788730 startingPage "775" @default.
• W3146788730 abstract "A clinical trial (RACAT) reported the noninferiority of triple therapy compared to biologic agents (etanercept + methotrexate), and previous studies confirmed that biologic disease-modifying antirheumatic drugs (bDMARDs) are more expensive but less beneficial than triple therapy for patients with rheumatoid arthritis (RA) in whom methotrexate (MTX) fails. However, from the perspective of the Chinese healthcare system, the cost-effectiveness of triple therapy versus bDMARD treatment sequences as a first-line therapy for patients with RA is still unclear. An individual patient simulation model was used to extrapolate the lifetime cost and health outcomes by tracing patients from initial treatment through switches to further treatment lines in a sequence. Therapeutic efficacy and physical function were evaluated using the American College of Rheumatology (ACR) response, 28-Joint Disease Activity Score (DAS28), and Health Assessment Questionnaire score. All input parameters in the model were derived from published studies, national databases, local hospitals, and experts’ opinions. Both direct costs and indirect costs were taken into consideration. Probabilistic and one-way sensitivity analyses were performed to test the uncertainty of the model, as were multiple scenario analyses. The lifetime analysis demonstrated that triple therapy was associated with lower costs and quality-adjusted life years (QALYs) than bDMARD sequences. These resulted in incremental cost-effectiveness ratios (ICERs) ranging from $87,090/QALY to $104,032/QALY, higher than the willingness-to-pay (WTP) threshold in China ($30,950/QALY). The baseline DAS28 impacted the model outcomes the most. Scenario analyses indicated that adding triple therapy to bDMARD sequences as a first-, second-, third-, or fourth-line therapy is very cost-effective, at a WTP of $10,316/QALY. From a Chinese payer perspective, triple therapy as first-line treatment in treatment sequence could be regarded as cost-effectiveness option for patients who failed MTX, compared to bDMARDs as first-line treatment, and instead of prescribing triple therapy as a substitute for bDMARDs as a first-line treatment, adding triple therapy to the bDMARD treatment sequence is likely to be very cost-effective for patients with active RA compared to bDMARD sequences." @default.
• W3146788730 created "2021-04-13" @default.
• W3146788730 creator A5019010418 @default.
• W3146788730 creator A5025387435 @default.
• W3146788730 creator A5035411778 @default.
• W3146788730 creator A5057587462 @default.
• W3146788730 creator A5081185599 @default.
• W3146788730 date "2021-03-27" @default.
• W3146788730 modified "2023-10-16" @default.
• W3146788730 title "Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure" @default.
• W3146788730 cites W1045948345 @default.
• W3146788730 cites W1579601585 @default.
• W3146788730 cites W1588610010 @default.
• W3146788730 cites W1701993624 @default.
• W3146788730 cites W1761300068 @default.
• W3146788730 cites W1766022638 @default.
• W3146788730 cites W1970491232 @default.
• W3146788730 cites W1999306257 @default.
• W3146788730 cites W2002814457 @default.
• W3146788730 cites W2010496466 @default.
• W3146788730 cites W2013161261 @default.
• W3146788730 cites W2022194132 @default.
• W3146788730 cites W2028764755 @default.
• W3146788730 cites W2082463046 @default.
• W3146788730 cites W2096839909 @default.
• W3146788730 cites W2102987799 @default.
• W3146788730 cites W2117738981 @default.
• W3146788730 cites W2119482170 @default.
• W3146788730 cites W2120393706 @default.
• W3146788730 cites W2133104890 @default.
• W3146788730 cites W2146166312 @default.
• W3146788730 cites W2149447280 @default.
• W3146788730 cites W2155402987 @default.
• W3146788730 cites W2163746267 @default.
• W3146788730 cites W2164521956 @default.
• W3146788730 cites W2166732840 @default.
• W3146788730 cites W2167297990 @default.
• W3146788730 cites W2339335481 @default.
• W3146788730 cites W2347164991 @default.
• W3146788730 cites W2420567828 @default.
• W3146788730 cites W2588618693 @default.
• W3146788730 cites W2623617647 @default.
• W3146788730 cites W2748149557 @default.
• W3146788730 cites W2768838210 @default.
• W3146788730 cites W2899653555 @default.
• W3146788730 cites W2913269790 @default.
• W3146788730 cites W2971217817 @default.
• W3146788730 cites W3011468725 @default.
• W3146788730 cites W3016320989 @default.
• W3146788730 cites W3086961895 @default.
• W3146788730 cites W3113161022 @default.
• W3146788730 cites W4211111012 @default.
• W3146788730 cites W4293302074 @default.
• W3146788730 doi "https://doi.org/10.1007/s40744-021-00300-4" @default.
• W3146788730 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8217385" @default.
• W3146788730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33772743" @default.
• W3146788730 hasPublicationYear "2021" @default.
• W3146788730 type Work @default.
• W3146788730 sameAs 3146788730 @default.
• W3146788730 citedByCount "4" @default.
• W3146788730 countsByYear W31467887302021 @default.
• W3146788730 countsByYear W31467887302022 @default.
• W3146788730 countsByYear W31467887302023 @default.
• W3146788730 crossrefType "journal-article" @default.
• W3146788730 hasAuthorship W3146788730A5019010418 @default.
• W3146788730 hasAuthorship W3146788730A5025387435 @default.
• W3146788730 hasAuthorship W3146788730A5035411778 @default.
• W3146788730 hasAuthorship W3146788730A5057587462 @default.
• W3146788730 hasAuthorship W3146788730A5081185599 @default.
• W3146788730 hasBestOaLocation W31467887301 @default.
• W3146788730 hasConcept C121955636 @default.
• W3146788730 hasConcept C126322002 @default.
• W3146788730 hasConcept C144133560 @default.
• W3146788730 hasConcept C1862650 @default.
• W3146788730 hasConcept C198451711 @default.
• W3146788730 hasConcept C2776999253 @default.
• W3146788730 hasConcept C2777226972 @default.
• W3146788730 hasConcept C2777575956 @default.
• W3146788730 hasConcept C2781059491 @default.
• W3146788730 hasConcept C6964187 @default.
• W3146788730 hasConcept C71924100 @default.
• W3146788730 hasConceptScore W3146788730C121955636 @default.
• W3146788730 hasConceptScore W3146788730C126322002 @default.
• W3146788730 hasConceptScore W3146788730C144133560 @default.
• W3146788730 hasConceptScore W3146788730C1862650 @default.
• W3146788730 hasConceptScore W3146788730C198451711 @default.
• W3146788730 hasConceptScore W3146788730C2776999253 @default.
• W3146788730 hasConceptScore W3146788730C2777226972 @default.
• W3146788730 hasConceptScore W3146788730C2777575956 @default.
• W3146788730 hasConceptScore W3146788730C2781059491 @default.
• W3146788730 hasConceptScore W3146788730C6964187 @default.
• W3146788730 hasConceptScore W3146788730C71924100 @default.
• W3146788730 hasFunder F4320321001 @default.
• W3146788730 hasFunder F4320322843 @default.
• W3146788730 hasIssue "2" @default.
• W3146788730 hasLocation W31467887301 @default.
• W3146788730 hasLocation W31467887302 @default.
• W3146788730 hasOpenAccess W3146788730 @default.

• next